Modality
Bispecific Ab
MOA
EZH2i
Target
EGFR
Pathway
RAS/MAPK
Bladder CaCF
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Aug 2031
Phase 2Current
NCT04174363
1,480 pts·CF
2018-07→2031-08·Recruiting
NCT06912077
1,986 pts·Bladder Ca
2020-02→2025-03·Terminated
3,466 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-161.0y agoPh2 Data· Bladder Ca
2031-08-085.4y awayPh2 Data· CF
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2025-03-16 · 1.0y ago
Bladder Ca
Ph2 Data
2031-08-08 · 5.4y away
CF
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04174363 | Phase 2 | CF | Recruiting | 1480 | MRD |
| NCT06912077 | Phase 2 | Bladder Ca | Terminated | 1986 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR |